SCHEMBL434917

SCHEMBL434917

C[C@H](NC(=O)CCN)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 1/20 0.50
FAAH O00519 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.46
SLC6A5 Q9Y345 1/20 0.46
GABRR1 P24046 2/20 0.41
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 1/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10650213 1.00 ALDH1A1 (0.50) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL434916 1.00 ALDH1A1 (0.50) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL19569859 0.88 FAAH (0.54) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL10768725 0.84 FAAH (0.59) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL5649671 0.83 FAAH (0.35) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL783990 0.82 SMN1; SMN2 (0.50) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL3145911 0.82 SMN1; SMN2 (0.50) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL564562 0.82 SMN1; SMN2 (0.50) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL9550539 0.82 FAAH (0.66) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5
SCHEMBL15602675 0.82 FAAH (0.66) ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152722-A1 DRUG CONJUGATE OF GLUCOCORTICOID SHANGHAI SENHUI MEDICINE CO., LTD. (CN) 2025-05-15 US claimed
CN-119894535-A Oritastatin derivatives and conjugates thereof 祐方有限公司 2025-04-25 CN claimed
WO-2025067446-A1 ANTIBODY-DRUG CONJUGATE TARGETING TROP2, AND PREPARATION METHOD AND USE THEREFOR 信达生物制药(苏州)有限公司 2025-04-03 WO claimed
CN-119119176-A Camptothecin derivatives 伊缪诺金公司 2024-12-13 CN claimed
EP-4470569-A1 DRUG CONJUGATE OF GLUCOCORTICOID Shanghai Shengdi Pharmaceutical Co., Ltd (CN) 2024-12-04 EP claimed
CN-113766954-B Camptothecin derivatives 伊缪诺金公司 2024-09-24 CN claimed
CN-118302199-A Anti-CDH 6 antibodies and antibody-drug conjugates thereof 普众发现医药科技(上海)有限公司 2024-07-05 CN claimed
WO-2024140917-A1 ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 上海盛迪医药有限公司 2024-07-04 WO claimed
EP-4374879-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE Shanghai Senhui Medicine Co., Ltd. (CN) 2024-05-29 EP claimed
US-20230144203-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2023-05-11 US claimed
EP-4094779-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE Shanghai Senhui Medicine Co., Ltd. (CN) 2022-11-30 EP claimed
EP-2119372-A1 Aroma compositions and preparations containing N-alpha-beta-alanyl-dipeptides Symrise GmbH & Co. KG (DE) 2009-11-18 EP claimed
US-5750555-A NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY GOEDECKE AKTIENGESELLSCHAFT (DE) 1998-05-12 US claimed
US-20250188115-A1 PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2025-06-12 US disclosed
US-20250152722-A1 DRUG CONJUGATE OF GLUCOCORTICOID SHANGHAI SENHUI MEDICINE CO., LTD. (CN) 2025-05-15 US disclosed
CN-119894535-A Oritastatin derivatives and conjugates thereof 祐方有限公司 2025-04-25 CN disclosed
EP-1971864-A2 KIT COMPRISING 2,4-DICHLOROPHENOXYACETIC ACD DERIVATIVES AND ANTIBODIES FOR HIGHLY SENSITIVE DETECTION ASSAYS Forschungszentrum Borstel (DE) 2008-09-24 EP disclosed
WO-2007051604-A2 NOVEL 2,4-DICHLOROPHENOXY ACETIC ACID DERIVATIVES AND USE THEREOF IN DIAGNOSTIC AND ANALYTIC DETECTION METHODS FORSCHUNGSZENTRUM BORSTEL (DE) 2007-05-10 WO disclosed
WO-2007051603-A2 KIT COMPRISING 2, 4- DICHLOROPHENOXYACETIC ACD DERIVATIVES AND ANTIBODIES FOR HIGHLY SENSITIVE DETECTION ASSAYS FORSCHUNGSZENTRUM BORSTEL (DE) 2007-05-10 WO disclosed
US-5750555-A NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY GOEDECKE AKTIENGESELLSCHAFT (DE) 1998-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188115-A1 PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE GLP1R, IAPP, GCG ALDH1A1 4794/4885MAPT 4749/4885FAAH 1458/4885
US-20250152722-A1 DRUG CONJUGATE OF GLUCOCORTICOID SHBG, CYP17A1, HSD17B7 ALDH1A1 378/4885MAPT 4035/4885FAAH 2679/4885
US-20230144203-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE ERLIN1, ERLIN2, EZR ALDH1A1 493/4885MAPT 2162/4885FAAH 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.